Fundamentals of Pharmaceutical Nanoscience (Hardcover) (ISBN-13: 9783031594779)

Professor Ijeoma F. Uchegbu

Ijeoma Uchegbu FMedSci is UCL's Professor of Pharmaceutical Nanoscience, a fellow of the Academy of Medical Sciences, an honorary fellow of the Royal Society of Chemistry, a governor on the Wellcome board (one of the largest biomedical sciences research charities in the world), a member of the Academy of Medical Sciences Council and Chief Scientific Officer of Nanomerics Ltd. In 2024, Uchegbu will take up the position of President of Wolfson College, University of Cambridge having been elected to the position in 2023. Uchegbu has served as Chair of the Academy of Pharmaceutical Sciences and chaired the UK's Engineering and Physical Sciences Research Council and Science Foundation Ireland grant prioritisation panels.

Uchegbu has studied the mechanisms of drug transport across biological barriers and created transformational drug transport nanoparticles. She was the first to show that peptides could be delivered across the blood brain barrier to elicit a pharmacological response, when presented as peptide drug nanofibers and the first to demonstrate, via definitive pharmacology and pharmacokinetics evidence, peptide transport into the brain, using peptide nanoparticles delivered via the nose to brain route. These findings led to the development of the enkephalin pain medicine candidate Envelta(TM), which was designed to address the opioid crisis. In preclinical studies, Envelta(TM) showed no analgesic tolerance, reward seeking behaviour or potential to cause significant constipation. Envelta has been out licensed for clinical development.

The technology underpinning Envelta(TM) won first prize in the Royal Society of Chemistry's Emerging Technologies competition in 2017 and the Academy of Pharmaceutical Sciences Science Innovation Award in 2016. Three other medicine candidates based on this nanotechnology have further been out-licensed to pharmaceutical companies.

Uchegbu has also won numerous prizes for her work and these include: the UK Government's Women of Outstanding Achievement in Science, Engineering and Technology 2007, Royal Pharmaceutical Society Pharmaceutical Scientist of the Year 2012, Special Recognition Business of Science Leadership Award 2023 and others.

Uchegbu's scientific research work has been funded continuously for over two decades by the UK's Engineering and Physical Sciences Research Council and she serves on the Biotechnology and Biological Sciences Research Council's governing body.

Dr Andreas G. Schatzlein

Andreas Schatzlein has a track record of medicines development and translational research in industry and academia. His research interests focus on the discovery and preclinical/clinical development of targeted anti-cancer drugs and nanomedicines and the understanding of their underlying biology. Andreas is a veterinary surgeon by training and, after completion of his doctorate on transdermal nanomedicines delivery, joined the biotech start-up IDEA in Munich to develop this technology commercially.

In 1996 joined academia at the Cancer Research UK Beatson Laboratories at the University of Glasgow where became leader of the Experimental Therapeutics and Gene Medicines Group. There he was also responsible for setting up a unit that carried out analysis of pharmacokinetics and pharmacodynamics readouts from early phase translational oncology/nanomedicines trials using a good clinical laboratory practice framework. He currently is a Reader at the UCL School of Pharmacy and co-founder and CEO of Nanomerics Ltd, a UCL spinout company developing pharmaceutical nanotechnology.

Dr Aikaterini Lalatsa

Aikaterini Lalatsa is a Reader in Nanomedicines and the Deputy Director of Cancer Research UK (CRUK) Formulation Unit (a MHRA licensed manufacturing unit for sterile and oral new Investigational Medicinal Products for Phase I/II clinical trials) at Strathclyde Institute of Pharmacy and Biomedical Sciences (SIPBS), University of Strathclyde. Katerina has a track record in development and translation of biologics, chemotherapeutics and nanomedicines working closely with industry towards translation into first in human studies. She leads the Bio-engineering, Biomaterials and Nanomedicine (BioN) laboratory (originally at University of Portsmouth and now at Strathclyde) that attracted funding from national and international government, charity or industrial sources. She is the inventor of 4 international patents and her work has led to a paradigm shift in the non-invasive delivery of peptides, proteins and antibodies and chemotherapeutics across the blood-brain barrier. Katerina is the MSc in Pharmaceutical Quality and Good Manufacturing Practise course leader at University of Strathclyde.

Porf. Dolores R. Serrano

Dolores received an European PhD with CUM LAUDE in 2013. After completing her doctorate studies, she worked as a postdoctoral Fellow at the School of Pharmacy and Pharmaceutical Sciences at Trinity College Dublin (Ireland) as part of SSPC consortium (Synthesis and Solid State Pharmaceutical Center). She was appointed as a lecturer in the Complutense University of Madrid in October 2015, and recently was promoted to Professor in 2023. She is the co-inventor of three patents and coauthor in over 80 publications. She received several scientific awards such as the Cantabria Labs Innovation Award in Dermatology in 2022, the Roche Institute Award in Digital Health in 2020, and the Research Pharmacy Award "Mario Martin Velamazan" in 2018. She has created one of the first 3D printing laboratory at the School of Pharmacy in Complutense University, being a referent on 3D printing of medicines. Her research team has also a consolidated background in 3D printing of microfluidic chips, especially for the manufacturing of nanomedicines, such as liposomes and nanoparticles.